Moleculin Biotech, Inc. beat EPS estimates 50% of the time across 2 reported quarters (1 beats, 1 misses). Data sourced from SEC EDGAR.
| Quarter | EPS Estimate | EPS Actual | Surprise | Result |
|---|---|---|---|---|
| Q22026 FY2026 | $-1.55 | $-1.40 | +9.7% | Beat |
| Q12026 FY2026 | $-1.69 | $-2.48 | -46.8% | Miss |
Back to MBRX overview · MBRX holders · MBRX KPIs
Data sourced from U.S. SEC EDGAR filings. Not personalized investment advice.